Phase II
Kyowa Kirin announced it is dropping its Parkinson’s disease candidate, KW-6356, a follow-up to Nourianz, despite promising Phase II data that showed the drug is “potentially effective.”
The agreement with Merck brings $290 million upfront to Orion to access the latter’s investigational candidate, ODM-208, for mCPRC and other related drugs.
Early data from Amgen’s ongoing trial on Lumakras for non-small cell lung cancer hinted at positive results from what could be a transformative combination of drugs versus cancer.
Atara announced that it has completed an interim analysis of its Phase II EMBOLD trial for the use of its candidate ATA188 in patients with progressive multiple sclerosis.
Nanoscope Therapeutics will make two presentations at the 2022 ASRS meeting on their gene therapy programs to treat degenerative retinal diseases, retinitis pigmentosa and Stargardt disease.
uniQure gave a 12-month update on AMT-130, the first-ever AAV gene therapy for HD to enter clinical trials. BioSpace spoke with the company’s president of R&D, Dr. Ricardo Dolmetsch.
Tonix Pharmaceuticals announced a mid-stage study for major depressive disorder, which followed the June disclosure of a Phase II study for a cocaine intoxication therapy.
The experimental drug, being developed to treat immunoglobulin A nephropathy, is IONIS-FB-L Rx, which hit the mark in a Phase II study showing a change in urinary protein after 29 weeks of treatment.
The study was assessing the investigational drug enoblituzumab as part of a combination therapy for head and neck cancer.
Weeks after BridgeBio presented positive biomarker data in Canavan Disease, gene therapy company Myrtelle added its own data to the emerging research space.
PRESS RELEASES